Creative Planning’s AbCellera Biologics ABCL Stock Holding History

Creative Planning’s Portfolio ABCL Stock Details ABCL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$154K	Buy	44,051 +2,207	+5%	+$7.94K	﹤0.01%	3807
2025 Q4	$143K	Sell	41,844 -5,889	-12%	-$26.3K	﹤0.01%	3642
2025 Q3	$240K	Buy	47,733 +6,730	+16%	+$29.7K	﹤0.01%	3325
2025 Q2	$141K	Buy	41,003 +2,656	+7%	+$6.61K	﹤0.01%	3352
2025 Q1	$85.5K	Sell	38,347 -33,079	-46%	-$94.9K	﹤0.01%	3275
2024 Q4	$209K	Buy	71,426 +35,627	+100%	+$99.2K	﹤0.01%	2944
2024 Q3	$93.1K	Buy	+35,799	New	+$99.2K	﹤0.01%	3029
2024 Q2	–	Sell	-11,589	Closed	-$52.5K	–	3064
2024 Q1	$52.5K	Sell	11,589 -2,131	-16%	-$10.9K	﹤0.01%	2779
2023 Q4	$78.3K	Buy	+13,720	New	+$63.6K	﹤0.01%	2599
2023 Q3	–	Sell	-11,703	Closed	-$75.6K	–	2904
2023 Q2	$75.6K	Buy	+11,703	New	+$79.9K	﹤0.01%	2393

Other funds holding ABCL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

TWC

TD Waterhouse Canada Toronto, Ontario, Canada $33.7B AUM 35.49% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Creative Planning's ABCL Position: Q1 2026 in Review

Creative Planning increased its AbCellera Biologics (ABCL) stake by 5.3% in Q1 2026, buying an estimated $7.94K and bringing the position to 44,051 shares worth $154K. The position accounts for ﹤0.01% of the portfolio, ranked #3807.

Creative Planning first reported a position in ABCL in Q2 2023 and has held it in 10 quarters since. The position peaked at $240K in Q3 2025. 138 funds tracked by Wall St. Rank hold ABCL as of Q1 2026.

Creative Planning held 44,051 shares of AbCellera Biologics worth $154K as of Q1 2026.
Creative Planning bought 2,207 AbCellera Biologics shares in Q1 2026, an estimated $7.94K.
AbCellera Biologics made up ﹤0.01% of Creative Planning's portfolio in Q1 2026, its #3807 holding.
Creative Planning first reported a position in AbCellera Biologics in Q2 2023 and has held it in 10 quarters since.
Creative Planning's AbCellera Biologics position peaked at $240K in Q3 2025.
138 funds tracked by Wall St. Rank held AbCellera Biologics as of Q1 2026.

Based on Creative Planning's 13F filing for Q1 2026, filed 12 May 2026.